OBJECTIVE: To assess safety, preliminary efficacy, and acceptability of the Shang Ring, a novel disposable device for adult male circumcision in Kenya. METHODS: Forty HIV-negative men were recruited in Homa Bay, Kenya. Circumcisions were performed by a trained physician or nurse working with 1 assistant. Follow-up was conducted at 2, 7, 9, 14, 21, 28, 35, and 42 days after circumcision. Rings were removed on day 7. Pain was assessed using a visual analog scale (VAS) (0 = no pain, 10 = worst possible). Men were interviewed at enrollment and on days 7 and 42. RESULTS: All 40 procedures were completed successfully. Mean procedure and device removal times were 4.8 (SD ± 2.0) and 3.9 (SD ± 2.6) minutes, respectively. There were 6 mild adverse events, including 3 penile skin injuries, 2 cases of edema, and 1 infection; all resolved with conservative management. In addition, there were 3 partial ring detachments between days 2-7. None required treatment or early ring removal. Erections with the ring were well tolerated, with a mean pain score of 3.5 (SD ± 2.3). By day 2, 80% of men were back to work. At 42 days, all participants were very satisfied with their circumcision and would recommend the procedure to others. CONCLUSIONS: Our results demonstrate that the Shang Ring is safe for further study in Africa. Acceptability of the Shang Ring among participants was excellent. With short procedure times, less surgical skill required, and the ease with which it can be used by nonphysicians, the Shang Ring could facilitate rapid roll-out of male circumcision in sub-Saharan Africa.
OBJECTIVE: To assess safety, preliminary efficacy, and acceptability of the Shang Ring, a novel disposable device for adult male circumcision in Kenya. METHODS: Forty HIV-negative men were recruited in Homa Bay, Kenya. Circumcisions were performed by a trained physician or nurse working with 1 assistant. Follow-up was conducted at 2, 7, 9, 14, 21, 28, 35, and 42 days after circumcision. Rings were removed on day 7. Pain was assessed using a visual analog scale (VAS) (0 = no pain, 10 = worst possible). Men were interviewed at enrollment and on days 7 and 42. RESULTS: All 40 procedures were completed successfully. Mean procedure and device removal times were 4.8 (SD ± 2.0) and 3.9 (SD ± 2.6) minutes, respectively. There were 6 mild adverse events, including 3 penile skin injuries, 2 cases of edema, and 1 infection; all resolved with conservative management. In addition, there were 3 partial ring detachments between days 2-7. None required treatment or early ring removal. Erections with the ring were well tolerated, with a mean pain score of 3.5 (SD ± 2.3). By day 2, 80% of men were back to work. At 42 days, all participants were very satisfied with their circumcision and would recommend the procedure to others. CONCLUSIONS: Our results demonstrate that the Shang Ring is safe for further study in Africa. Acceptability of the Shang Ring among participants was excellent. With short procedure times, less surgical skill required, and the ease with which it can be used by nonphysicians, the Shang Ring could facilitate rapid roll-out of male circumcision in sub-Saharan Africa.
Authors: Jason Bailey Reed; Emmanuel Njeuhmeli; Anne Goldzier Thomas; Melanie C Bacon; Robert Bailey; Peter Cherutich; Kelly Curran; Kim Dickson; Tim Farley; Catherine Hankins; Karin Hatzold; Jessica Justman; Zebedee Mwandi; Luke Nkinsi; Renee Ridzon; Caroline Ryan; Naomi Bock Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731
Authors: Nancy S Padian; Sandra I McCoy; Salim S Abdool Karim; Nina Hasen; Julia Kim; Michael Bartos; Elly Katabira; Stefano M Bertozzi; Bernhard Schwartländer; Myron S Cohen Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Richard Lee; E Charles Osterberg; Philip S Li; Marc Goldstein; Mark Barone; Stephanie L Combes; David Sokal; Ron Gray; Godfrey Kigozi; Stephen Watya Journal: J Acquir Immune Defic Syndr Date: 2013-10-01 Impact factor: 3.731
Authors: Godfrey Kigozi; Richard Musoke; Stephen Watya; Nehemiah Kighoma; Paschal Ssebbowa; David Serwadda; Fred Nalugoda; Frederick Makumbi; Philip Li; Richard Lee; Marc Goldstein; Maria Wawer; Nelson Sewankambo; Ronald H Gray Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731
Authors: Samuel Kanyago; David M Riding; Elichum Mutakooha; Alcides Lopez de la O; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2013-10-01 Impact factor: 3.731
Authors: Brian J Morris; Jake H Waskett; Joya Banerjee; Richard G Wamai; Aaron A R Tobian; Ronald H Gray; Stefan A Bailis; Robert C Bailey; Jeffrey D Klausner; Robin J Willcourt; Daniel T Halperin; Thomas E Wiswell; Adrian Mindel Journal: BMC Pediatr Date: 2012-02-28 Impact factor: 2.125